References
- Allegra CJ, Rumble RB, Hamilton SR, et al (2016). Extended ras gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: american society of clinical oncology provisional clinical opinion update 2015. J Clin Oncol, 34, 179-85. https://doi.org/10.1200/JCO.2015.63.9674
- Al-Kuraya KS (2009). KRAS and TP53 mutations in colorectal carcinoma. Saudi J Gastroenterol, 15, 217-9. https://doi.org/10.4103/1319-3767.56087
- Brink M, Weijenberg MP, de Goeij AF, et al (2005). Dietary folate intake and k-ras mutations in sporadic colon and rectal cancer in The Netherlands Cohort Study. Int J Cancer, 114, 824-30. https://doi.org/10.1002/ijc.20775
- Bokemeyer C, Bondarenko I, Makhson A, et al (2009). Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol, 27, 663-71. https://doi.org/10.1200/JCO.2008.20.8397
- Inoue Y, Saigusa S, Iwata T, et al (2012). The prognostic value of KRAS mutations in patients with colorectal cancer. Oncol Rep, 28, 1579-84. https://doi.org/10.3892/or.2012.1974
- Lievre A, Bachet J, Le Corre D, et al (2006). KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res, 66, 3992-5. https://doi.org/10.1158/0008-5472.CAN-06-0191
- Liu X, Jakubowski M, Hunt JL (2011). KRAS gene mutation in colorectal cancer is correlated with increased proliferation and spontaneous apoptosis. Am J Clin Pathol, 135, 245-52. https://doi.org/10.1309/AJCP7FO2VAXIVSTP
- Li Z, Chen Y, Wang D, et al (2012). Detection of KRAS mutations and their associations with clinicopathological features and survival in Chinese colorectal cancer patients. J Int Med Res, 40, 1589-98. https://doi.org/10.1177/147323001204000439
- Margonis GA, Kim Y, Spolverato G, et al (2015). Association between specific mutations in KRAS codon 12 and colorectal liver metastasis. JAMA Surg, 150, 722-9. https://doi.org/10.1001/jamasurg.2015.0313
- Modest DP, Stintzing S, Laubender RP, et al (2011). Clinical characterization of patients with metastatic colorectal cancer depending on the KRAS status. Anticancer Drugs, 22, 913-8. https://doi.org/10.1097/CAD.0b013e3283493160
- Neumann J, Zeindl-Eberhart E, Kirchner T, et al (2009). Frequency and type of KRAS mutations in routine diagnostic analysis of metastatic colorectal cancer. Pathol Res Pract, 205, 858-62. https://doi.org/10.1016/j.prp.2009.07.010
- Omidifar N Md, Geramizadeh B Md, Mirzai M Ms (2015). K-ras mutation in colorectal cancer, a report from southern Iran. Iran J Med Sci, 40, 454-60.
- Payandeh M, Sadeghi E, Sadeghi M, et al (2015a). Chronic myeloid leukemia in patient with local recurrence colon cancer: a case report. Int J Cancer Research, 11, 197-200. https://doi.org/10.3923/ijcr.2015.197.200
- Payandeh M, Sadeghi M, Sadeghi E, et al (2015b). Analysis of KRAS, BRAF and NRAS in Patients with Colorectal Cancer: the First Report of Western Iran. Am J Cancer Prevent, 3, 19-22.
- Payandeh M, Sadeghi M, Sadeghi E (2016). The report of KRAS mutation and NRAS wild-type in a patient with thyroid metastasis from colon cancer: a rare case report. Iran J Pathol, 11, 71-5.
- Russo A, Rizzo S, Bronte G, et al (2009). The long and winding road to useful predictive factors for anti-EGFR therapy in metastatic colorectal carcinoma: the KRAS/BRAF pathway. Oncol, 77, 57-68. https://doi.org/10.1159/000258497
- Roock WD, Vriendt VD, Normanno N, et al (2011). KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol, 12, 594-603. https://doi.org/10.1016/S1470-2045(10)70209-6
- Sameer AS, Chowdhri NA, Abdullah S, et al (2009). Mutation pattern of K-ras gene in colorectal cancer patients of Kashmir: a report. Indian J Cancer, 46, 219-25. https://doi.org/10.4103/0019-509X.52956
- Shen H, Yuan Y, Hu HG, et al (2011). Clinical significance of K-ras and BRAF mutations in Chinese colorectal cancer patients. World J Gastroenterol, 17, 809-16. https://doi.org/10.3748/wjg.v17.i6.809
- Tan C, Du X (2012). KRAS mutation testing in metastatic colorectal cancer. World J Gastroenterol, 18, 5171-80.
- Wilson PM, Labonte MJ, Lenz HJ (2010). Molecular markers in the treatment of metastatic colorectal cancer. Cancer J, 16, 262-72. https://doi.org/10.1097/PPO.0b013e3181e07738
- Yokota T, Shibata N, Ura T, et al (2010). Cycleave polymerase chain reaction method is practically applicable for V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog (KRAS)/Vraf murine sarcoma viral oncogene homolog B1 (BRAF) genotyping in colorectal cancer. Transl Res, 156, 98-105. https://doi.org/10.1016/j.trsl.2010.05.007
Cited by
- gene mutation report in sporadic colorectal cancer, from Northwest of Iran vol.5, pp.3, 2017, https://doi.org/10.1002/ccr3.779